Clinical trials: Thymus Neoplasms
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
HEARTS Trial for Thoracic Cancers
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the…
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III
- Trial name
- NCT07132918
- Testing
- MRgART, LINAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Thymoma and Thymic Carcinoma, Pleural Metastasis
Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural Metastasis
This trial plans to conduct a prospective, randomized controlled phase II clinical study to explore the efficacy and safety of hypofractionated radiotherapy guided by optical surface imaging combined with FBCT in patients with…
- Trial name
- NCT07879417
- Testing
- hypofractionated radiotherapy guided by optical surface imaging and FBCT, hypofractionated radiotherapy guided by CBCT
- Volunteers
- 234 people
- Sponsor
- Sun Yat-sen University
Efgartigimod, Intravenous Immunoglobulin
EFG vs IVIG in TAMG
This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor…
- Conditions
- Efgartigimod, Intravenous Immunoglobulin, Myasthenia Gravis Associated With Thymoma
- Trial name
- NCT07231523
- Testing
- Efgartigimod + Thymectomy, Intravenous immunglobulin + Thymectomy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Zhongshan Hospital
Mesolthelioma, Esophageal Cancer
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Background: Recent research has shown that causing an immune response to tumor cells may help slow or stop the growth of tumors.
- Conditions
- Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas
- Trial name
- NCT01258868
- Testing
- Celebrex, Tumor cell vaccine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Stomach Neoplasms
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. Mesothelioma accounts for 0.10% of deaths annually in the United States.
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Trial name
- NCT01950572
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Background: The current standard of care for advanced lung cancer and cancers of the thymus consists primarily of chemotherapy treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Trial name
- NCT01306045
- Testing
- AZD6244, MK-2206, Lapatinib
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thymoma and Thymic Carcinoma
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Given the high expression of IGF-1R and pAKT proteins in thymoma tissues, able to sensitize tumors to mTOR inhibition, and the anticancer activity of the mTOR inhibitors, clinical evaluation in thymoma and thymic carcinoma seems…
- Trial name
- ONC-2010-001 (NCT02049047)
- Testing
- Everolimus
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Armando Santoro, MD
Pleural Metastases, Breast Cancer
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options.
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT01163552
- Testing
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Candidiasis, Chronic Mucocutaneous
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or…
- Trial name
- CAMB (NCT02629419)
- Testing
- Amphotericin B
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis.
- Trial name
- NCT03288662
- Testing
- CT and histopathological classification
- Volunteers
- 2 people
- Sponsor
- Military Hospital 103
Pancreatic Cancer, Thymic Cancer
Genetic Evaluation of Families With Endocrine Cancers
This study is being conducted to identify altered genetic factors that may exist and influence endocrine cancers in unrelated MEN1 families with different cancers.
- Conditions
- Pancreatic Cancer, Thymic Cancer, Parathyroid Disease, MEN1 Syndrome
- Trial name
- MEN1 (NCT01794676)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Jersey Shore University Medical Center
Poor Thymic Function, Immunodeficiency
Expanded Access Protocol Thymus Transplantation
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation.
- Conditions
- Poor Thymic Function, Immunodeficiency, Athymia, Immunoreconstitution
- Trial name
- NCT02274662
- Testing
- Cultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
- Volunteers
- 11 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Hypothesis 1- Using IMRT, the radiation therapy (RT) dose can be safely escalated from 58 Gy to 74 Gy given as 6 fractions/week with concurrent chemotherapy.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
- Trial name
- ESIMRT (NCT00921739)
- Testing
- Esophageal sparing IMRT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University